Pajuelo-Revilla tested positive for the presence of 19-norandrosterone and Isotope Ratio Mass Spectrometry (IRMS) analysis that reflected values consistent with the exogenous origin of testosterone and its metabolites, both anabolic steroids that are prohibited at all times, in a urine sample that was collected out of competition on August 5, 2024, in Lima, Peru. A subsequent sample collected from Pajuelo-Revilla on August 21, 2024, in Sao Paulo, Brazil, also tested positive for 19-norandrosterone and IRMS analysis consistent with the exogenous origin of testosterone. Pajuelo-Revilla admitted the use of deca-durabolin (nandrolone) leading up to these sample collections.
CSAD determined that an appropriate sanction for Pajuelo-Revilla’s adverse findings is a 24-month period of ineligibility.